Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Doherty K, Barry M, Belisario JM, Morrison C, Car J, Doherty G. Personal information and public health: design tensions in sharing and monitoring wellbeing in pregnancy. Int J Hum Comput Stud. 2020 Mar;135:102373. doi: 10.1016/j.ijhcs.2019.102373
Ellermann M, Gharaibeh RZ, Fulbright L, Dogan B, Moore LN, Broberg CA, Lopez LR, Rothemich AM, Herzog JW, Rogala A, Gordon IO, Rieder F, Brouwer CR, Simpson KW, Jobin C, Sartor RB, Arthur JC. Yersiniabactin-producing adherent/invasive escherichia coli promotes inflammation-associated fibrosis in gnotobiotic Il10-/- mice. Infect Immun. 2019 Oct 18;87(11):e00587-19. doi: 10.1128/IAI.00587-19
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603